Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea
NCT ID: NCT02362711
Last Updated: 2019-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
248 participants
INTERVENTIONAL
2015-02-28
2017-01-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea
NCT01129102
Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea
NCT05900336
Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea
NCT04541134
A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea
NCT03448536
Treatment of Primary Menstrual Pain With Kanion Capsule
NCT00523146
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NPC-16 Standard Dosing Regimen Group
Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
NPC-16 Standard Dosing Regimen Group
NPC-16 Continuous Dosing Regimen Group
Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
NPC-16 Continuous Dosing Regimen Group
Placebo Group
Placebo for NPC-16
Placebo Group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NPC-16 Standard Dosing Regimen Group
NPC-16 Continuous Dosing Regimen Group
Placebo Group
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnant woman
16 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nobelpharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tasuku Harada, MD, PhD
Role: STUDY_CHAIR
Tottori University
Mikio Momoeda, MD, PhD
Role: STUDY_CHAIR
St. Luke's International Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NPC-16-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.